Menu
Back to User profile » Ms Lianchun Xiao
Papers published by Ms Lianchun Xiao:
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Journal of Hepatocellular Carcinoma 2024, 11:455-461
Published Date: 4 March 2024
Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development
Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM
Journal of Hepatocellular Carcinoma 2022, 9:823-837
Published Date: 15 August 2022
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A
Journal of Hepatocellular Carcinoma 2021, 8:1129-1145
Published Date: 9 September 2021
Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO
Journal of Hepatocellular Carcinoma 2020, 7:143-153
Published Date: 16 September 2020
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC
OncoTargets and Therapy 2016, 9:773-780
Published Date: 15 February 2016